Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pegylated interferon Alfa-2a and hydroxyurea in polycythemia vera and essential thrombocythemia: differential cellular and molecular responses.

Leukemia - 1 Aug 2018

Tashi Tsewang, Swierczek Sabina, Kim Soo Jin, Salama Mohamed E, Song Jihyun, Heikal Nahla, King Katherine Y, Hickman Kim, Litton Scott, Prchal Josef T

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Hydroxyurea
Share to Interferon-alpha
Share to Janus Kinase 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Polycythemia Vera

Share to Polyethylene Glycols

Share to Thrombocythemia, Essential

Share to Tumor Cells, Cultured

Source

Open in PubMed Open full text

Identifiers

PMID: 29556018
DOI: 10.1038/s41375-018-0080-6
PMCID: PMC6552660

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pegylated interferon Alfa-2a and hydroxyurea in polycythemia vera and essential thrombocythemia: differential cellular and molecular responses.PMID 29556018Read ↗

Pegylated interferon: the who, why, and howSemantic proximity Read ↗

Evidence and expertise in the management of polycythemia vera and essential thrombocythemia.Semantic proximity Read ↗

Contemporary Use of Interferon Therapy in the Myeloproliferative Neoplasms.Semantic proximity Read ↗

Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.Semantic proximity Read ↗

Polycythemia Vera: Rapid Evidence Review.Semantic proximity Read ↗

Interferon apha 2b for treating patients with JAK2V617F positive polycythemia vera and essential thrombocytosis.Semantic proximity Read ↗

Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?Semantic proximity Read ↗

How I treat polycythemia vera.Semantic proximity Read ↗

Interferon α-2b gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation.Semantic proximity Read ↗

Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a.Semantic proximity Read ↗

Interferon alfa therapy in CALR-mutated essential thrombocythemia.Semantic proximity Read ↗

Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.